# Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

> **NCT03471728** · — · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 2475 (actual)

## Conditions studied

- Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases)
- Irritable Bowel Syndrome With Constipation (IBS-C)

## Interventions

- **DRUG:** linaclotide

## Key facts

- **NCT ID:** NCT03471728
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-02
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 2475 (ACTUAL)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03471728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03471728, "Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03471728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*